Menu
Menu
BioReperia
Optimizing treatment through personalized medicine and streamlining the drug discovery process by increasing the pre-clinical drug development.
- Biotech, Healthtech
- Series A
Location
Linköping, Sweden
Revenue size
EUR 480,000
Year founded
2015
Funding raised
~EUR 1 million
Founders
Lasse Jensen & Anna Fahlgren
Most relevant investors
Life Science Invest Gamma
Team size
1 - 10
Problem
Identifying patients likely to benefit from treatment beforehand is vital to improve treatment outcomes and survival rates, as two out of three cancer treatments fail. Moreover, late-stage drug failures due to efficacy issues result in significant time, money, and effort losses for drug discovery companies, hindering their ability to provide potential benefits to patients.
SOLUTION
BioReperia’s ZTX® platform rapidly identifies the best treatment for each cancer patient within 5 days, assessing metastasis risk and tumor regression regardless of mutations, applicable to all cancer types. Additionally, it speeds up drug discovery by providing accurate in vivo data on tumor regression and metastasis inhibition, improving lead candidate selection and advancing cancer drug development, especially in immuno-oncology, by replicating the tumor microenvironment with tumor stroma and immune cells.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
BioReperia’s ZTX®Predict is a precision medicine product aimed at healthcare providers and the pharma industry to provide clinical decision support and run clinical trials, while ZTX® Oncoleads is a drug discovery product that provides the pharma industry with tools for drug screening and development.
Team
Starting as a spinoff from Linköping University, the BioReperia team has a broad and deep experience within their field, and has grown to include PhDs, R&D specialists, and project managers to support the further growth and development of the company.
Unique selling point
BioReperia’s unique ZTX® platform provides in-vivo data on tumor regression and metastasis inhibition of compounds as a tool for personalized medicine and drug development